within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BB07_Nelarabine;

model Nelarabine
  extends Pharmacolibrary.Drugs.ATC.L.L01BB07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01BB07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nelarabine is a prodrug of the deoxyguanosine analogue ara-G, approved for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in both pediatric and adult patients. It is used when the disease has not responded to, or has relapsed following, at least two chemotherapy regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adults and pediatric patients with refractory or relapsed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma following intravenous administration.</p><h4>References</h4><ol><li><p>Dyakonova, YY, et al., &amp; Karachunskiy, AI (2018). The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience. <i>Terapevticheskii arkhiv</i> 90(7) 38–50. DOI:<a href=&quot;https://doi.org/10.26442/terarkh201890738-50&quot;>10.26442/terarkh201890738-50</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30701921/&quot;>https://pubmed.ncbi.nlm.nih.gov/30701921</a></p></li><li><p>Kurtzberg, J, et al., &amp; Mitchell, BS (2005). Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 23(15) 3396–3403. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2005.03.199&quot;>10.1200/JCO.2005.03.199</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15908652/&quot;>https://pubmed.ncbi.nlm.nih.gov/15908652</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Nelarabine;
